Imaging key biomarkers of tumor angiogenesis

Theranostics

Volumn 2, Issue 5, 2012, Pages 502-515

  Backer, Marina V ^a   Backer, Joseph M ^a  

^a SIBTECH INC   (United States)

Author keywords

Anti angiogenic therapy; Integrins; Molecular imaging; Tumor angiogenesis; VEGF receptors

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BIOLOGICAL MARKER; FLUORINE 18; INTEGRIN; PAZOPANIB; TECHNETIUM 99M; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EARLY DIAGNOSIS; FOCAL ADHESION; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR GROWTH; TUMOR REGRESSION;

EID: 84864543385     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3623     Document Type: Review

References (110)

1. Bussolati B, Grange C, Camussi G. Tumor exploits alternative strategies to achieve vascularization. FASEB J. 2011; 25:2874-82.
2. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspect Medicine. 2011; 32: 71-87.
3. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146: 873-87.
4. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nature Rev Cancer. 2008; 8: 592-603.
5. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refrac-toriness/resistance to anti-angiogenic therapies. Trend Pharmacol Sci. 2009; 30: 624-30.
6. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangio-genesis therapy. Eur J Cancer. 2010; 46: 1323-32.
7. Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochemical Pharmacology. 2011; 81: 1183-91.
8. Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Target. 2011; 11: 624-53.
9. Ribatti D. Novel angiogenesis inhibitors: addressing the issue of redun-dancy in the angiogenic signaling pathway. Cancer Treat Rev. 2011; 37: 344-52.
10. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nature Rev Cancer. 2008; 8: 604-17.
11. Legate KR, Montañez E, Kudlacek O, Füssler R. ILK, PINCH and parvin: the tIPP of integrin signaling. Nature Rev Mol Cell Biol.2006; 7: 20-31.
12. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Met Rev. 2008; 27: 631-44.
13. Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspect Med. 2011; 32: 88-111.
14. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011; 437: 169-83.
15. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Network. 2009; 20: 158-63.
16. Schliemann C, Neri D. Antibody-based vascular tumor targeting. Recent Res Cancer Res. 2010;180: 201-16.
17. Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehi-cles. Integr Biol Quant Biosci Nano Macro. 2010; 2: 326-37.
18. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999; 40: 1061-71.
19. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res. 2009; 42: 969-80.
20. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci. 2009; 14: 887-99.
21. Pan D, Pramanik M, Senpan A, et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J. 2011; 25: 875-82.
22. Anderson CR, Hu X, Zhang H, et al. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol. 2011; 46: 215-24.
23. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chem. 2003; 9: 2717-25.
24. Poethko T, Schottelius M, Thumshirn G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med 2004; 45: 892-902.
25. Poethko T, Schottelius M, Thumshirn G, et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim Acta, 2004; 92: 317-27.
26. Liu S, Hsieh WY, Jiang Y, et al. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem 2007; 18: 438-46.
27. Li ZB, Cai W, Cao Q, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expres-sion. J Nucl Med 2007; 48: 1162-71.
28. Liu Z, Liu S, Wang F, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG(4) linkers. Eur J Nucl Med Mol Imaging 2009; 36: 1296-307.
29. Sancey L, Garanger E, Foillard S, et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther J Am Soc Gene Ther. 2009; 17: 837-43.
30. Mulder WJ, Castermans K, van Beijnum JR, et al. Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis. 2009; 12: 17-24.
31. Kessinger CW, Khemtong C, Togao O, et al. In vivo angiogenesis imag-ing of solid tumors by alpha(v)beta(3)-targeted, dual-modality micellar nanoprobes. Exp Biol Med. 2010; 235: 957-65.
32. Chen W, Jarzyna PA, van Tilborg GA, et al. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 2010; 24: 1689-99.
33. Akers WJ, Zhang Z, Berezin M, et al. Targeting of al-pha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles. Nanomed. 2010; 5: 715-26.
34. Goutayer M, Dufort S, Josserand V, et al. Tumor targeting of functional-ized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm. 2010; 75: 137-47.
35. Yang X, Hong H, Grailer JJ, et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for tar-geted anticancer drug delivery and PET/MR imaging. Biomater. 2011; 32: 4151-60.
36. Edwards WB, Akers WJ, Ye Y, et al. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imag. 2009; 8: 101-10.
37. Yu MK, Park J, Jeong YY, et al. Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imag-ing and drug delivery. Nanotech. 2010; 21: 415102.
38. Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Curr Med Chem Anti-Cancer Agents. 2007; 7: 552-8.
39. Xie H, Diagaradjane P, Deorukhkar AA, et al. Integrin al-phavbeta3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomed. 2011; 6: 259-69.
40. Ferl GZ, Dumont RA, Hildebrandt IJ, et al. Derivation of a compart-mental model for quantifying 64Cu-DOTA-RGD kinetics in tu-mor-bearing mice. J Nucl Med 2009; 50: 250-8.
41. Jin ZH, Razkin J, Josserand V, et al. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4). Mol Imag. 2007; 6: 43-55.
42. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhib-itors. Nature Med. 2009; 15: 392-400.
43. Jung KH, Lee KH, Paik JY, et al. Favorable biokinetic and tu-mor-targeting properties of 99mTclabeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006; 47: 2000-7.
44. Palmowski M, Huppert J, Ladewig G, et al. Molecular profiling of angi-ogenesis with targeted ultrasound imaging: early assessment of antian-giogenic therapy effects. Mol Cancer Ther. 2008; 7: 101-9.
45. Palmowski M, Peschke P, Huppert J, et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. Neoplasia. 2009; 11: 856-63.
46. Morrison MS, Ricketts SA, Barnett J, et al. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009; 50: 116-22.
47. Battle MR, Goggi JL, Allen L, et al. Monitoring tumor response to anti-angiogenic sunitinib therapy with 18F-Fluciclatide, an 18F-labeled and alpha;V{beta}3-integrin and alpha;V{beta}5-integrin imaging agent. J Nucl Med 2011; 52: 424-430.
48. Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett. 2006; 16: 6190-3.
49. Dumont RA, Hildebrandt I, Su H, et al. Noninvasive imaging of al-phaVbeta3 function as a predictor of the antimigratory and antiprolifer-ative effects of dasatinib. Cancer Res. 2009; 69: 3173-9.
50. Yang M, Gao H, Yan Y, et al. PET imaging of early response to the tyro-sine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011, 38: 1237-47.
51. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated avh3 integrin in cancer patients by positron emission tomog-raphy and [18F]galacto- RGD. PLoS Med 2005; 2:e70.
52. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacoki-netics of the αvβ3 selective tracer 18F Galacto-RGD in cancer patients. J Nucl Med. 2005; 46: 1333-41.
53. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]galacto-RGD identifies the level of integrin avh3 expression in man. Clin Cancer Res 2006; 12:3942-9.
54. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto- RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med. 2006; 47: 763-9.
55. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of avb3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007; 13: 6610-16.
56. Beer AJ, Niemeyer M, Carlsen J, et al. Comparison of integrin al-phaVbeta3 expression and glucose metabolism in primary and meta-static lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008; 49:22-9.
57. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008; 49: 255-9.
58. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-Oncology. 2009; 11: 861-70.
59. Bach-Gansmo T, Danielsson R, Saracco A, et al. (2006). Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006; 47: 1434-39.
60. Bach-Gansmo T, Skretting A, Bogsrud TV. Integrin scintimammography using a dedicated breast imaging, solid-state γ-camera and 99mTc-labelled NC100692. Clin Phys Funct Imag. 2008; 28: 235-9.
61. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study Group. An open-label, multicenter, phase 2a study to assess the feasibil-ity of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Ra-diologica. 2010; 51: 40-6.
62. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the posi-tron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008; 49: 879-86.
63. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosi-metric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging alpha(v)beta(3) integrin levels. Radiol. 2011; 260: 182-91.
64. Cornelissen B, Oltenfreiter R, Kersemans V, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol. 2005; 32: 431-6.
65. Yoshimoto M, Kinuya S, Kawashima A, et al. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. Nucl Med Biol. 2006; 33: 963-9.
66. Li S, Peck-Radosavljevic M, Kienast O, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) re-ceptor scintigraphy. Annal Oncol. 2003; 14: 1274-77.
67. Li S, Peck-Radosavljevic M, Kienast O, et al. Iodine-123-vascular endo-thelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma Q J Nucl Med Mol Imag. 2004; 48: 198-206.
68. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006; 47: 2048-2056.
69. Wang H, Cai W, Chen K, et al. A new PET tracer specific for vascular endothelial growth factor receptor. Eur J Nucl Med Mol Imag. 2007; 34: 2001-10.
70. Cai W, Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci. 2007; 12: 4267-79.
71. Cai W, Guzman R, Hsu AR, et al. Positron emission tomography imag-ing of poststroke angiogenesis. Stroke. 2009; 40: 270-7.
72. Chen K, Cai W, Li ZB, et al. Quantitative PET imaging of VEGF receptor expression. Mol Imag Biol. 2009; 11: 15-22.
73. Chen K, Li ZB, Wang H, et al. Dual-modality optical and positron emis-sion tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imag. 2008; 35: 2235-44.
74. Lu E, Wagner WR, Schellenberger U, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identifica-tion of ischemic tissue. Circulation 2003; 108: 97-103.
75. Chan C, Sandhu J, Guha A, et al. A human transferrin(hnTf)-VEGF fusion protein containing an integrated binding site for 111In for im-aging tumor angiogenesis. J Nucl Med 2005; 46: 1745-52.
76. Wang H, Chen K, Niu G, Chen X. Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogene-sis. Mol Pharmac. 2009; 6: 285-94.
77. Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther. 2005; 4: 1423-9.
78. Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angio-genesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 2006; 33: 841-48.
79. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nature Med. 2007; 13: 504-9.
80. Backer MV, Levashova Z, Levenson R, et al. Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol. 2008; 494: 275-94.
81. Eder M, Krivoshein AV, Backer M, et al. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombi-nant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol. 2010; 37: 405-12.
82. Blom E, Velikyan I, Monazzam A, et al. Synthesis and characterization of scVEGF-PEG-[68Ga]NOTA and scVEGF-PEG-[68Ga]DOTA PET tracers. J Labl Compd Radiopharm. 2011; [Epub ahead of print]
83. Levashova Z, Backer M, Backer JM, Blankenberg FG. Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Biocon-jug Chem. 2008; 19: 1049-54.
84. Anderson CR, Rychak JJ, Backer M, et al. scVEGF microbubble ultra-sound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invst Radiol. 2010; 45: 579-85.
85. Blankenberg FG, Levashova Z, Sarkar SK et al. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol. 2010; 3: 56-64.
86. Levashova Z, Backer M, Hamby CV, et al. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med. 2010; 51: 959-66.
87. Blankenberg FG, Levashova Z, Goris MG, et al. Targeted systemic radi-otherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. J Nucl Med. 2011; 52: 1630-37.
88. Ali MM, Janic B, Babajani-Feremi A, et al. Changes in vascular permea-bility and expression of different angiogenic factors following an-ti-angiogenic treatment in rat glioma. PLoS ONE 2010; 5(1): e8727.
89. Virostko J, Xie J, Hallahan DE, et al. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small ani-mals. Mol Imag Biol. 2009; 11: 204-12.
90. Rychak JJ, Graba J, Cheung AM, et al. Microultrasound molecular im-aging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imag. 2007; 6: 289-96.
91. Liu H, Wang X, Tan KB, et al. Molecular imaging of vulnerable plaques in rabbits using contrast-enhanced ultrasound targeting to vascular en-dothelial growth factor receptor-2. J Clin Ultrasound. 2011; 39: 83-90.
92. Deshpande N, Ren Y, Foygel K, et al. Tumor angiogenic marker expres-sion levels during tumor growth: longitudinal assessment with molecu-larly targeted microbubbles and US imaging. Radiol. 2011; 258: 804-11.
93. Lee CM, Kim EM, Cheong SJ, et al. Targeted molecular imaging of VEGF receptors overexpressed in ischemic microvasculature using chi-tosan-DC101 conjugates. J Biomed Materials Res. Part A. 2010; 92: 1510-7.
94. Brunel FM, Lewis JD, Destito G, et al. Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett. 2010; 10: 1093-7.
95. Tardy I, Pochon S, Theraulaz M, et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Inv Radiol. 2010; 45: 573-8.
96. Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Inv Radiol. 2010; 45: 89-95.
97. Ilovich O, Jacobson O, Aviv Y, et al. Formation of fluorine-18 labeled diaryl ureas--labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis. Bioorg Med Chem. 2008; 16: 4242-51.
98. Samen E, Thorell JO, Lu L, et al. Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2. Eur J Nucl Med Mol Imag. 2009; 36:1283-95.
99. Gao M, Lola CM, Wang M, et al. Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. Bioorg Med Chem Lett. 2011; 21: 3222-6.
100. Gautier B, Goncalves V, Diana D, et al. Biochemical and structural analy-sis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010; 53: 4428-40.
101. Dineen SP, Sullivan LA, Beck AW, et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer. 2008; 8: 352.
102. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinet-ic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antian-giogenic activity. Mol. Cancer Ther. 2007; 6: 2012-21.
103. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol-Hematol. 2011; 77: 163-71.
104. Nagengast WB, Lub-de Hooge MN, Oosting SF, et al. VEGF-PET imag-ing is a noninvasive biomarker showing differential changes in the tu-mor during sunitinib treatment. Cancer Res. 2011; 71: 143-53.
105. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-31.
106. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91: 1071-121.
107. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic im-plications. Curr Opin Gen Dev. 2011; 21: 73-9.
108. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nature Rev Clin Oncol. 2010; 7: 455-65.
109. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15: 232-39.
110. Gerger A, LaBonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J. 2011; 17: 134-41.